1. Home
  2. SSP vs NGNE Comparison

SSP vs NGNE Comparison

Compare SSP & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo E.W. Scripps Company (The)

SSP

E.W. Scripps Company (The)

HOLD

Current Price

$3.45

Market Cap

303.7M

Sector

Industrials

ML Signal

HOLD

Logo Neurogene Inc.

NGNE

Neurogene Inc.

HOLD

Current Price

$17.02

Market Cap

327.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SSP
NGNE
Founded
1878
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Broadcasting
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
303.7M
327.8M
IPO Year
1988
N/A

Fundamental Metrics

Financial Performance
Metric
SSP
NGNE
Price
$3.45
$17.02
Analyst Decision
Buy
Strong Buy
Analyst Count
2
7
Target Price
$5.95
$40.14
AVG Volume (30 Days)
491.4K
145.7K
Earning Date
02-25-2026
03-23-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,318,706,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$9.11
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.36
$6.88
52 Week High
$4.98
$37.27

Technical Indicators

Market Signals
Indicator
SSP
NGNE
Relative Strength Index (RSI) 42.04 41.27
Support Level $3.30 $18.12
Resistance Level $3.73 $18.95
Average True Range (ATR) 0.18 1.34
MACD 0.01 0.00
Stochastic Oscillator 27.62 16.23

Price Performance

Historical Comparison
SSP
NGNE

About SSP E.W. Scripps Company (The)

The E W Scripps Co is a media enterprise with interests in local and national media brands. It owns and operates a collection of daily and community newspapers in medium-sized cities in the southern and western portions of the United States. The company's operating segment includes Local Media, Scripps Networks, and Other. It generates maximum revenue from the Local Media segment. The Local Media segment includes local broadcast stations and their related digital operations.

About NGNE Neurogene Inc.

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

Share on Social Networks: